These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15791501)

  • 21. Disodium clodronate in painful nonresponsive periarthropathy of the hip.
    Monteforte P; Molfetta L; Grillo G; Brignone A; Rovetta G
    Int J Tissue React; 2000; 22(4):111-5. PubMed ID: 11199340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clodronate in the management of bone metastases: a clinical study of 91 patients.
    Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
    Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clodronate in treatment of tumor osteopathy. Evaluation in tumor patients with bone metastases or hypercalcemia].
    Voigtmann R; Kirstein A
    Fortschr Med; 1994 Feb; 112(4):43-6. PubMed ID: 7512066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid.
    Rossini M; Viapiana O; Ramonda R; Bianchi G; Olivieri I; Lapadula G; Adami S
    Rheumatology (Oxford); 2009 Jul; 48(7):773-8. PubMed ID: 19406908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible.
    Montonen M; Kalso E; Pylkkären L; Lindströrm BM; Lindqvist C
    Int J Oral Maxillofac Surg; 2001 Aug; 30(4):313-7. PubMed ID: 11518354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clodronate in the prevention and treatment of skeletal metastasis.
    Gulley J; Dahut WL
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):221-30. PubMed ID: 15877520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
    Heidenreich A
    Urologe A; 1997 Nov; 36(6):568. PubMed ID: 9487597
    [No Abstract]   [Full Text] [Related]  

  • 29. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [An experience with combined therapy of radiation and Bonephos for osteolytic metastases of breast cancer].
    Poliakov PIu; Larionova NA; Bychenkov OA; Moc'kin VG
    Vopr Onkol; 1999; 45(3):311-3. PubMed ID: 10443239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain and pain alleviation in hospital-based home care: demographic, biological and treatment factors.
    Heedman PA; Strang P
    Support Care Cancer; 2003 Jan; 11(1):35-40. PubMed ID: 12527952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
    Vorreuther R; Klotz T; Engelking R
    Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.
    Cresswell SM; English PJ; Hall RR; Roberts JT; Marsh MM
    Br J Urol; 1995 Sep; 76(3):360-5. PubMed ID: 7551847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
    Kylmälä T; Taube T; Tammela TL; Risteli L; Risteli J; Elomaa I
    Br J Cancer; 1997; 76(7):939-42. PubMed ID: 9328156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
    Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
    Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.